Compare TOI & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOI | PYPD |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.1M | 66.2M |
| IPO Year | N/A | 2020 |
| Metric | TOI | PYPD |
|---|---|---|
| Price | $3.37 | $3.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.0M | 87.0K |
| Earning Date | 11-13-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $461,039,000.00 | N/A |
| Revenue This Year | $28.51 | N/A |
| Revenue Next Year | $23.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $0.20 | $2.30 |
| 52 Week High | $4.88 | $4.07 |
| Indicator | TOI | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 53.86 |
| Support Level | $3.23 | $3.89 |
| Resistance Level | $3.90 | $4.05 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 36.63 | 20.83 |
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.